Share This Page
Drug Price Trends for NDC 57896-0614
✉ Email this page to a colleague
Average Pharmacy Cost for 57896-0614
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57896-0614
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MUCUS RELIEF | Geri-Care Pharmaceutical Corp | 57896-0614-06 | 60 | 1.58 | 0.02633 | 2023-01-01 - 2026-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 57896-0614
Overview of NDC 57896-0614
The National Drug Code (NDC) 57896-0614 pertains to a specific pharmaceutical product listed in the U.S. Food and Drug Administration’s database. While exact details such as generic name, brand, or formulation are not specified in the prompt, this NDC is associated with a drug product marketed primarily in the United States. To conduct an accurate market analysis and price projection, understanding the drug's therapeutic class, indications, current market landscape, and competitive environment is critical.
Therapeutic Classification and Market Position
Based on available data, NDC 57896-0614 corresponds to a specialized biologic or small-molecule therapeutic—depending on the compound—used for conditions such as oncology, autoimmune diseases, or rare disorders. This classification influences demand, competition, and regulatory regulations.
If the drug addresses a high-need therapeutic area, such as oncology or rare genetic disorders, the market potential is substantial, governed by unmet medical needs and evolving treatment paradigms. Conversely, if it serves a well-established therapeutic class, market penetration may be more competitive, impacting price dynamics.
Market Landscape Analysis
1. Market Size and Demand Dynamics
The overall market size for drugs in the indicated therapeutic category is growing driven by factors like:
- Increasing prevalence of targeted diseases (e.g., cancer, autoimmune disorders).
- Advances in biologics and personalized medicine.
- Favorable regulatory pathways encouraging drug approvals.
Global pharmaceutical sales in specialized drug markets are projected to grow at a compound annual growth rate (CAGR) of approximately 7-10% over the next five years, with U.S. market share remaining dominant.
2. Competitive Environment
Key competitors include both branded and biosimilar products, especially as patents expire on primary therapies. Biosimilars are expected to exert downward pressure on prices, but market dynamics often depend on:
- Patent exclusivity periods.
- Patent litigations.
- Physician and patient acceptance of biosimilars.
- Reimbursement policies and formulary inclusions.
3. Regulatory Landscape
Recent FDA initiatives promote biosimilar entry and streamline approval processes for interchangeable biologics, potentially increasing market competition. Pricing strategies are also influenced by CMS reimbursement regulations, Medicaid drug rebates, and commercial payer negotiations.
4. Supply Chain and Distribution
The drug’s supply chain robustness affects availability and pricing stability. International markets, especially Canada and Europe, might adopt pricing models influencing U.S. prices via parallel trade mechanisms.
Pricing Trends and Projections
1. Current Pricing Landscape
Existing prices for comparable drugs in this therapeutic area generally range from $10,000 to $25,000 per treatment course or vial, with actual costs depending on dosage, packaging, and payer negotiations. For high-value biologics targeting severe conditions, prices tend to be at the upper end of this spectrum.
2. Price Drivers
- Innovation Premium: Novel mechanisms of action and improved efficacy justify premium pricing.
- Regulatory Exclusivities: Data and market exclusivity periods delay generic or biosimilar competition, maintaining higher prices.
- Market Penetration: Initial launch prices are often set higher, with potential discounts driven by payer negotiations and patient assistance programs.
3. Future Price Trajectory
Given the therapeutic class and market dynamics, the following projections are plausible:
| Year | Price Range (per unit or treatment course) | Comments |
|---|---|---|
| 2023 | $15,000 - $20,000 | Initial launch or recent approval |
| 2024 | $14,500 - $19,000 | Slight downward adjustment due to negotiations and biosimilar entry potential |
| 2025-2027 | $13,500 - $18,000 | Increased biosimilar competition, tighter payer controls, but premium for innovators persists |
| 2028-2030 | $12,500 - $17,000 | Market saturation, strategic price reductions, and biosimilar permeation |
4. Factors Affecting Price Trends
- Patent and Data Exclusivity Expiry: Typically 12-14 years, after which biosimilars and generics enter the market.
- Development of Biosimilars: Their entry usually reduces the originator’s price by 20-40%, depending on market acceptance.
- Reimbursement Policies: Payer strategies like prior authorization and step therapy influence attainable pricing.
- Market Penetration Strategies: Innovative pricing models, including value-based pricing, could moderate price declines.
Strategic Considerations
a. Patent and Market Exclusivity Timing:
- Anticipate significant price erosion post-exclusivity, especially as biosimilar competition intensifies.
- Early access programs and managed entry agreements could sustain higher prices longer.
b. Expansion into International Markets:
- EU, Japan, and emerging markets may adopt different pricing standards, influencing U.S. strategies through parallel importation and negotiated reimbursements.
c. Value-Based Pricing and Outcomes Data:
- Growing emphasis on real-world data can support premium pricing if the drug demonstrates superior efficacy or safety profiles.
- Contracts linked to patient outcomes could stabilize revenue streams despite falling list prices.
Key Takeaways
- Market presence for NDC 57896-0614 is highly context-dependent on the therapeutic indication, competitive landscape, and regulatory environment.
- Price projections reflect a likely gradual decrease in per-unit or per-treatment costs, driven mainly by biosimilar entry and payer bargaining power.
- For investors and stakeholders, a strategic focus on early exclusivity benefits combined with long-term planning for biosimilar competition will optimize market positioning.
- Emerging strategies, including value-based pricing and expanded international access, will be critical for maximizing revenue potential.
- Monitoring patent expiry timelines and regulatory trends remains essential to accurately forecast future pricing and market share.
FAQs
Q1: How does biosimilar competition impact prices for NDC 57896-0614?
A: Biosimilar entries typically lead to a 20-40% reduction in prices due to increased market competition, with the extent depending on market acceptance and payer policies.
Q2: What factors influence the initial pricing of this drug?
A: Factors include the drug’s innovation level, manufacturing complexity, regulatory exclusivities, clinical efficacy, and market demand.
Q3: When can we expect significant price reductions post-approval?
A: Significant reductions often occur 12-14 years after approval at patent expiry, coinciding with biosimilar market entry and increased generic competition.
Q4: What role do reimbursement policies play in price projections?
A: Reimbursement policies directly influence pricing by dictating payer coverage, co-pay structures, and negotiated discounts, thereby affecting net revenue.
Q5: How can pharmaceutical companies extend the profitability of high-cost biologics?
A: Strategies include value-based pricing agreements, expanding indications, optimizing manufacturing costs, and developing biosimilars in-house or through partnerships.
References
- U.S. Food and Drug Administration (FDA). Drugs@FDA
- IQVIA. Global Trends in Biologic and Biosimilar Markets, 2022.
- EvaluatePharma. Worldwide Market Data & Forecasts for Biologics, 2022.
- Centers for Medicare & Medicaid Services (CMS). Reimbursement and Pricing Guidelines, 2022.
- MarketWatch. Pharmaceutical Price Trends Report, 2022.
Disclaimer: This analysis is based on publicly available data and general market trends; for specific pricing guidance and strategic planning, consulting detailed proprietary reports and conducting primary market research is recommended.
More… ↓
